Romidepsin

ISTODAX is indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: ISTODAX is indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy.

What it is used for

Romidepsin injection is indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy.

Side effects, and when to stop

The following clinically significant adverse reactions are described in more detail in other sections of the prescribing information.

Myelosuppression
Infections
Electrocardiographic Changes
Tumor Lysis Syndrome

Who should not take it

None.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Romidepsin; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/romidepsin
APA 7th: sofidex. (2026, August 3). Romidepsin. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/romidepsin
AMA 11th: Romidepsin. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/romidepsin

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.